+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Childhood Absence Epilepsy Treatment Market by Treatment Type, Drug Class, End User, Distribution Channel - Global Forecast to 2030- Product Image
Childhood Absence Epilepsy Treatment Market by Treatment Type, Drug Class, End User, Distribution Channel - Global Forecast to 2030- Product Image
Sale

Childhood Absence Epilepsy Treatment Market by Treatment Type, Drug Class, End User, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 194 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6010834
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Childhood Absence Epilepsy Treatment Market grew from USD 255.22 million in 2024 to USD 274.62 million in 2025. It is expected to continue growing at a CAGR of 7.46%, reaching USD 393.11 million by 2030.

Understanding the Evolving Dynamics of Childhood Absence Epilepsy Treatment

Childhood absence epilepsy poses unique clinical and therapeutic challenges that demand rigorous analysis and strategic foresight. While historically considered a benign pediatric condition, recent research has illuminated the long-term cognitive and psychosocial ramifications of recurrent absence seizures. As clinical guidelines evolve and new therapies emerge, stakeholders-from clinicians to payers and manufacturers-must navigate a rapidly shifting terrain. This executive summary synthesizes the critical developments shaping the market, offering decision-makers a clear window into treatment innovation, regulatory dynamics, and patient-centered considerations.

Balancing the therapeutic promise of novel interventions against practical considerations such as safety, accessibility, and cost containment is more vital than ever. By examining each facet of the landscape-from medical devices and dietary approaches to drug classes and distribution channels-this report equips leaders with the nuanced intelligence necessary to optimize clinical outcomes and commercial performance. Through comprehensive analysis and thought leadership, the ensuing sections illuminate the forces propelling change, enabling stakeholders to make informed choices that prioritize patient well-being and sustainable growth.

Emerging Paradigms Redefining Childhood Absence Epilepsy Care

The past few years have witnessed a seismic shift in the management of childhood absence epilepsy, driven by breakthroughs in precision medicine and digital health integration. Advances in genetic profiling and neuroimaging now allow clinicians to tailor therapeutic regimens with unprecedented accuracy, reducing trial-and-error prescribing and expediting seizure control. Concurrently, the advent of remote monitoring platforms has empowered caregivers and healthcare teams to track seizure frequency in real time, fostering proactive interventions and improving adherence.

Dietary therapies have likewise undergone transformation, with refined ketogenic and modified Atkins protocols designed to enhance tolerability and nutritional balance. Complementing these metabolic approaches, neurostimulation modalities such as deep brain stimulation and vagus nerve stimulation are gaining traction in refractory cases, offering alternative pathways when pharmacotherapy falls short. Collectively, these developments signify a departure from one-size-fits-all paradigms toward a cohesive ecosystem in which personalized care, data-driven insights, and multidisciplinary collaboration converge to redefine the standard of treatment.

Assessing the Ripple Effect of U.S. Tariff Reforms on 2025 Treatment Access

United States tariff adjustments scheduled for 2025 are poised to ripple across the childhood absence epilepsy treatment market, reshaping cost structures and supply chain dynamics. Proposed duties on active pharmaceutical ingredients and medical device components may elevate production expenses, with manufacturers potentially passing incremental costs to downstream stakeholders. This scenario underscores the imperative for agility in procurement strategies and underscores the value of diversified sourcing to mitigate exposure to tariff-induced price volatility.

Furthermore, elevated import levies on specialized nutritional compounds integral to therapeutic diets could constrain access in certain regions, necessitating adaptive distribution models. Pharmaceutical companies and device manufacturers are proactively revisiting contractual agreements and exploring localized manufacturing partnerships to buffer against tariff-related headwinds. While the precise financial impact will hinge on final tariff rates, the overarching narrative emphasizes resilience and strategic foresight as essential attributes for organizations committed to maintaining continuity of care and safeguarding affordability for vulnerable pediatric populations.

Decoding Market Segments to Unveil Strategic Opportunities

Decoding market segments reveals intricate patterns that inform resource allocation and product development priorities. When viewed through the lens of treatment modalities, anti-seizure medication commands the lion’s share of clinical focus, encompassing core compounds such as ethosuximide, lamotrigine, levetiracetam, and valproate. Each of these agents plays a distinct role in individualized regimens, with ethosuximide serving as first-line therapy for absence seizures and alternative agents positioned for refractory presentations. In parallel, dietary therapy-represented by classical ketogenic diets and modified Atkins regimens-remains a critical adjunct, offering metabolic seizure control where pharmacotherapy alone is insufficient. Neurostimulation further broadens the therapeutic toolkit, with deep brain stimulation and vagus nerve stimulation emerging as viable options for children unresponsive to conventional interventions.

Examining drug classes as a standalone segmentation underscores the competitive dynamics among ethosuximide, lamotrigine, levetiracetam, and valproate. Market share oscillations reflect clinical guideline updates, patent expirations, and safety profile considerations, driving shifts in prescribing behavior. End-user analysis illuminates the diverse environments where care is administered: home care settings managed either by caregiver support or professional nursing teams; hospital environments spanning both inpatient wards and outpatient clinics; and specialized epilepsy monitoring units and pediatric neurology centers where advanced diagnostics and multidisciplinary care converge. Distribution channel segmentation highlights the varied pathways through which treatment modalities reach patients, ranging from hospital pharmacies and retail dispensaries to burgeoning online pharmacy platforms that offer enhanced convenience and broader geographic reach.

Regional Variance Shaping Treatment Pathways Across Major Markets

Regional variations profoundly shape the childhood absence epilepsy treatment paradigm. In the Americas, a robust infrastructure of academic research centers and comprehensive care networks accelerates clinical trial activity and the adoption of cutting-edge therapies. Reimbursement frameworks in this region have evolved to accommodate high-cost interventions, though emerging tariff policies introduce new layers of complexity in pricing negotiations.

Europe, Middle East & Africa presents a mosaic of regulatory environments and healthcare delivery models. Western Europe leads in guideline harmonization and access to neurostimulation technologies, while certain markets in Eastern Europe and the Middle East endeavor to enhance capacity through public-private partnerships and telemedicine initiatives. Africa’s landscape is marked by initiatives to expand diagnostic reach in resource-constrained settings, underscoring the importance of cost-efficient pharmaceutical formulations and nutritional interventions.

Asia-Pacific encapsulates both mature markets, where generics drive pricing competition, and rapidly developing economies investing in specialized care centers. Government-led programs in countries such as Japan and Australia prioritize pediatric neurological health, while emerging markets in Southeast Asia navigate infrastructure challenges. Across all subregions, digital health solutions are gaining traction as a means to bridge gaps in specialist availability and foster remote collaboration.

Competitive Landscape Spotlight: Pioneers and Innovators

Key players within the childhood absence epilepsy ecosystem are pursuing diverse strategies to consolidate market position and catalyze innovation. Leading pharmaceutical companies with heritage in anti-seizure medications continue to refine extended-release formulations and pursue label expansions backed by real-world evidence. Simultaneously, device manufacturers are investing in next-generation neurostimulation platforms that integrate closed-loop feedback and artificial intelligence-driven algorithms to optimize therapeutic dosing.

Collaborative ventures between drug developers and nutrition specialists have generated proprietary dietary compounds designed for palatability and compliance, while targeted acquisitions have expanded portfolios to encompass complementary modalities. Several organizations are exploring strategic partnerships with technology firms to imbue monitoring devices with predictive analytics, enabling preemptive seizure alerts. This convergence of life sciences, medical devices, and software underscores a broader competitive dynamic: market leadership will accrue to those entities capable of orchestrating end-to-end treatment ecosystems that elevate patient outcomes and forge resilient, patient-centric value propositions.

Strategic Actions to Drive Growth and Patient Outcomes

To thrive amid evolving market dynamics, industry leaders should recalibrate their strategic playbooks along four critical dimensions. First, fortify supply chain resilience by diversifying manufacturing partnerships and evaluating onshore production options to insulate against tariff fluctuations. Second, invest in digital health integration by embedding remote monitoring and telehealth capabilities into existing product lines, thereby enhancing adherence and enabling proactive clinical intervention. Third, pursue collaborative R&D models that align pharmaceutical, device, and nutritional expertise, accelerating the development of comprehensive treatment pathways that address multifaceted patient needs. Finally, engage payers and policymakers early to co-create value-based frameworks that link reimbursement to demonstrable clinical outcomes, ensuring sustainable access to high-impact therapies for pediatric populations.

By enacting these targeted measures, organizations can navigate regulatory headwinds, capitalize on emergent technologies, and reinforce their positioning as trusted partners in delivering holistic care for children with absence epilepsy.

Rigorous Methodology Underpinning a Robust Market Analysis

This analysis is underpinned by a rigorous, multi-method research framework designed to ensure accuracy and relevance. Primary research included in-depth interviews with neurologists, dietitians, healthcare administrators, and patient advocacy representatives to capture frontline perspectives on therapeutic efficacy, access barriers, and unmet needs. Secondary research sources comprised peer-reviewed journals, clinical trial registries, regulatory filings, and proprietary databases documenting drug approvals, reimbursement policies, and device clearances.

Data triangulation techniques were employed to reconcile disparate inputs, while trend extrapolation prioritized recent developments in digital health and tariff policy changes. Segmentation and regional analyses adhered to standardized market taxonomy, enabling consistent comparisons across modalities, end users, and geographic territories. Quality assurance protocols, including peer review and editorial validation, were rigorously applied to guarantee methodological transparency and minimize bias, ensuring stakeholders can rely on the insights presented to inform strategic decision-making.

Synthesizing Insights to Navigate Future Pathways

In synthesizing the multifaceted landscape of childhood absence epilepsy treatment, several overarching themes emerge: the critical role of personalized interventions, the disruptive potential of digital health solutions, and the strategic imperative of tariff risk mitigation. As new therapies advance through clinical pipelines and policy environments evolve, stakeholders must remain agile, collaborative, and outcome-focused. By embracing integrated treatment ecosystems that harmonize pharmacology, nutrition, and technology, the industry can elevate standards of care and drive tangible improvements in patient quality of life. The insights delineated herein furnish a strategic blueprint for aligning innovation with operational excellence, empowering leaders to navigate complexity and deliver enduring value in a dynamic market.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Treatment Type
    • Anti-Seizure Medication
      • Ethosuximide
      • Lamotrigine
      • Levetiracetam
      • Valproate
    • Dietary Therapy
      • Ketogenic Diet
      • Modified Atkinson Regimen
    • Neurostimulation
      • Deep Brain Stimulation
      • Vagus Nerve Stimulation
  • Drug Class
    • Ethosuximide
    • Lamotrigine
    • Levetiracetam
    • Valproate
  • End User
    • Home Care Settings
      • Caregiver Managed
      • Home Nursing
    • Hospitals
      • Inpatient
      • Outpatient
    • Specialty Clinics
      • Epilepsy Monitoring Units
      • Pediatric Neurology Centers
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • AbbVie Inc.
  • GlaxoSmithKline plc
  • UCB S.A.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Pfizer Inc.
  • Johnson & Johnson
  • Novartis AG

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Childhood Absence Epilepsy Treatment Market, by Treatment Type
8.1. Introduction
8.2. Anti-Seizure Medication
8.2.1. Ethosuximide
8.2.2. Lamotrigine
8.2.3. Levetiracetam
8.2.4. Valproate
8.3. Dietary Therapy
8.3.1. Ketogenic Diet
8.3.2. Modified Atkinson Regimen
8.4. Neurostimulation
8.4.1. Deep Brain Stimulation
8.4.2. Vagus Nerve Stimulation
9. Childhood Absence Epilepsy Treatment Market, by Drug Class
9.1. Introduction
9.2. Ethosuximide
9.3. Lamotrigine
9.4. Levetiracetam
9.5. Valproate
10. Childhood Absence Epilepsy Treatment Market, by End User
10.1. Introduction
10.2. Home Care Settings
10.2.1. Caregiver Managed
10.2.2. Home Nursing
10.3. Hospitals
10.3.1. Inpatient
10.3.2. Outpatient
10.4. Specialty Clinics
10.4.1. Epilepsy Monitoring Units
10.4.2. Pediatric Neurology Centers
11. Childhood Absence Epilepsy Treatment Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies
12. Americas Childhood Absence Epilepsy Treatment Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Childhood Absence Epilepsy Treatment Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Childhood Absence Epilepsy Treatment Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. AbbVie Inc.
15.3.2. GlaxoSmithKline plc
15.3.3. UCB S.A.
15.3.4. Sanofi S.A.
15.3.5. Sun Pharmaceutical Industries Ltd.
15.3.6. Teva Pharmaceutical Industries Ltd.
15.3.7. Viatris Inc.
15.3.8. Pfizer Inc.
15.3.9. Johnson & Johnson
15.3.10. Novartis AG
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET MULTI-CURRENCY
FIGURE 2. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET MULTI-LANGUAGE
FIGURE 3. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ETHOSUXIMIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY LAMOTRIGINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY LEVETIRACETAM, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY VALPROATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY KETOGENIC DIET, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY MODIFIED ATKINSON REGIMEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DEEP BRAIN STIMULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY VAGUS NERVE STIMULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ETHOSUXIMIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY LAMOTRIGINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY LEVETIRACETAM, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY VALPROATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY CAREGIVER MANAGED, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME NURSING, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY INPATIENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY EPILEPSY MONITORING UNITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY PEDIATRIC NEUROLOGY CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 65. CANADA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 66. CANADA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, 2018-2030 (USD MILLION)
TABLE 67. CANADA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2030 (USD MILLION)
TABLE 68. CANADA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2030 (USD MILLION)
TABLE 69. CANADA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 70. CANADA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 71. CANADA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 72. CANADA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 73. CANADA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 74. CANADA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 75. MEXICO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 76. MEXICO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, 2018-2030 (USD MILLION)
TABLE 77. MEXICO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2030 (USD MILLION)
TABLE 78. MEXICO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2030 (USD MILLION)
TABLE 79. MEXICO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 80. MEXICO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 81. MEXICO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 82. MEXICO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 83. MEXICO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 84. MEXICO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2030 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 116. UNITED KINGDOM CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 117. UNITED KINGDOM CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, 2018-2030 (USD MILLION)
TABLE 118. UNITED KINGDOM CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2030 (USD MILLION)
TABLE 119. UNITED KINGDOM CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2030 (USD MILLION)
TABLE 120. UNITED KINGDOM CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 121. UNITED KINGDOM CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 122. UNITED KINGDOM CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 123. UNITED KINGDOM CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 124. UNITED KINGDOM CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 125. UNITED KINGDOM CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 126. GERMANY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 127. GERMANY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, 2018-2030 (USD MILLION)
TABLE 128. GERMANY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2030 (USD MILLION)
TABLE 129. GERMANY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2030 (USD MILLION)
TABLE 130. GERMANY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 131. GERMANY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 132. GERMANY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 133. GERMANY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 134. GERMANY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 135. GERMANY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 136. FRANCE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 137. FRANCE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, 2018-2030 (USD MILLION)
TABLE 138. FRANCE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2030 (USD MILLION)
TABLE 139. FRANCE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2030 (USD MILLION)
TABLE 140. FRANCE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 141. FRANCE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 142. FRANCE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 143. FRANCE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 144. FRANCE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 145. FRANCE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 146. RUSSIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 147. RUSSIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, 2018-2030 (USD MILLION)
TABLE 148. RUSSIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2030 (USD MILLION)
TABLE 149. RUSSIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2030 (USD MILLION)
TABLE 150. RUSSIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 151. RUSSIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 152. RUSSIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 153. RUSSIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 154. RUSSIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 155. RUSSIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 156. ITALY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 157. ITALY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, 2018-2030 (USD MILLION)
TABLE 158. ITALY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2030 (USD MILLION)
TABLE 159. ITALY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2030 (USD MILLION)
TABLE 160. ITALY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 161. ITALY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 162. ITALY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 163. ITALY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 164. ITALY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 165. ITALY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 166. SPAIN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 167. SPAIN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, 2018-2030 (USD MILLION)
TABLE 168. SPAIN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2030 (USD MILLION)
TABLE 169. SPAIN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2030 (USD MILLION)
TABLE 170. SPAIN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 171. SPAIN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 172. SPAIN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 173. SPAIN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 174. SPAIN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 175. SPAIN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 176. UNITED ARAB EMIRATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 177. UNITED ARAB EMIRATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, 2018-2030 (USD MILLION)
TABLE 178. UNITED ARAB EMIRATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2030 (USD MILLION)
TABLE 179. UNITED ARAB EMIRATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2030 (USD MILLION)
TABLE 180. UNITED ARAB EMIRATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 181. UNITED ARAB EMIRATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 186. SAUDI ARABIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 187. SAUDI ARABIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, 2018-2030 (USD MILLION)
TABLE 188. SAUDI ARABIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2030 (USD MILLION)
TABLE 189. SAUDI ARABIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2030 (USD MILLION)
TABLE 190. SAUDI ARABIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 191. SAUDI ARABIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 192. SAUDI ARABIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 193. SAUDI ARABIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 194. SAUDI ARABIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 196. SOUTH AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 197. SOUTH AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, 2018-2030 (USD MILLION)
TABLE 198. SOUTH AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2030 (USD MILLION)
TABLE 199. SOUTH AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2030 (USD MILLION)
TABLE 200. SOUTH AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 202. SOUTH AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 204. SOUTH AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 206. DENMARK CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 207. DENMARK CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, 2018-2030 (USD MILLION)
TABLE 208. DENMARK CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2030 (USD MILLION)
TABLE 209. DENMARK CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2030 (USD MILLION)
TABLE 210. DENMARK CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 211. DENMARK CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 212. DENMARK CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 213. DENMARK CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 214. DENMARK CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 215. DENMARK CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 216. NETHERLANDS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 217. NETHERLANDS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, 2018-2030 (USD MILLION)
TABLE 218. NETHERLANDS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2030 (USD MILLION)
TABLE 219. NETHERLANDS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2030 (USD MILLION)
TABLE 220. NETHERLANDS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 221. NETHERLANDS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 222. NETHERLANDS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 223. NETHERLANDS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 224. NETHERLANDS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 225. NETHERLANDS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 226. QATAR CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 227. QATAR CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, 2018-2030 (USD MILLION)
TABLE 228. QATAR CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2030 (USD MILLION)
TABLE 229. QATAR CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2030 (USD MILLION)
TABLE 230. QATAR CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 231. QATAR CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 232. QATAR CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 233. QATAR CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 234. QATAR CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 235. QATAR CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 236. FINLAND CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 237. FINLAND CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, 2018-2030 (USD MILLION)
TABLE 238. FINLAND CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2030 (USD MILLION)
TABLE 239. FINLAND CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2030 (USD MILLION)
TABLE 240. FINLAND CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 241. FINLAND CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 242. FINLAND CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 243. FINLAND CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 244. FINLAND CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 245. FINLAND CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 246. SWEDEN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 247. SWEDEN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, 2018-2030 (USD MILLION)
TABLE 248. SWEDEN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2030 (USD MILLION)
TABLE 249. SWEDEN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2030 (USD MILLION)
TABLE 250. SWEDEN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 251. SWEDEN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 252. SWEDEN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 253. SWEDEN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 254. SWEDEN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 255. SWEDEN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 256. NIGERIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 257. NIGERIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, 2018-2030 (USD MILLION)
TABLE 258. NIGERIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2030 (USD MILLION)
TABLE 259. NIGERIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2030 (USD MILLION)
TABLE 260. NIGERIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 261. NIGERIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 262. NIGERIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 263. NIGERIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 264. NIGERIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 265. NIGERIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 266. EGYPT CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 267. EGYPT CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, 2018-2030 (USD MILLION)
TABLE 268. EGYPT CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2030 (USD MILLION)
TABLE 269. EGYPT CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2030 (USD MILLION)
TABLE 270. EGYPT CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 271. EGYPT CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 272. EGYPT CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 273. EGYPT CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 274. EGYPT CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 275. EGYPT CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 276. TURKEY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 277. TURKEY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, 2018-2030 (USD MILLION)
TABLE 278. TURKEY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2030 (USD MILLION)
TABLE 279. TURKEY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2030 (USD MILLION)
TABLE 280. TURKEY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 281. TURKEY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 282. TURKEY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 283. TURKEY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 284. TURKEY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 285. TURKEY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 286. ISRAEL CHILDHOO

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Childhood Absence Epilepsy Treatment market report include:
  • AbbVie Inc.
  • GlaxoSmithKline plc
  • UCB S.A.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Pfizer Inc.
  • Johnson & Johnson
  • Novartis AG

Table Information

Report AttributeDetails
No. of Pages194
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 274.62 Million
Forecasted Market Value ( USD ) by 2030 $ 393.11 Million
Compound Annual Growth Rate7.4%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Anti-Epileptic Drugs for Pediatrics - Global Stategic Business Report - Product Image

Anti-Epileptic Drugs for Pediatrics - Global Stategic Business Report

  • Report
  • 367 Pages
  • Global
From
Epilepsy Drugs Market Report 2025 - Product Image

Epilepsy Drugs Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Epilepsy Drugs - Global Strategic Business Report - Product Image

Epilepsy Drugs - Global Strategic Business Report

  • Report
  • 93 Pages
  • Global
From
Epilepsy Drug Market by Product Type, Patient Demographics, Treatment Type, Distribution Channel, Drug Class - Global Forecast to 2030 - Product Image

Epilepsy Drug Market by Product Type, Patient Demographics, Treatment Type, Distribution Channel, Drug Class - Global Forecast to 2030

  • Report
  • 199 Pages
  • Global
From
Epilepsy Drugs Market Size, Share & Trends Analysis Report by Treatment (First Generation Anti-Epileptics, Second Generation Anti-Epileptics), Distribution Channel, and Region with Growth Forecasts, 2025-2030 - Product Image

Epilepsy Drugs Market Size, Share & Trends Analysis Report by Treatment (First Generation Anti-Epileptics, Second Generation Anti-Epileptics), Distribution Channel, and Region with Growth Forecasts, 2025-2030

  • Report
  • 90 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.